Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 9/20 | 0.41 |
| ▸ | CA2 | P00918 | 9/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | GRK6 | P43250 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3718127 | 1.00 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL4286250 | 1.00 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL11198199 | 1.00 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6889028 | 1.00 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL5697577 | 1.00 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL8540328 | 0.99 | GSK3B (0.49) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6882003 | 0.89 | GSK3B (0.38) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL5697584 | 0.86 | GSK3B (0.49) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6882333 | 0.86 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6887317 | 0.86 | GSK3B (0.49) | GSK3BADKTSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2008-03-20 | — | — | US | claimed |
| US-20060122144-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2006-06-08 | — | — | US | claimed |
| EP-1581547-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2004050678-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2004-06-17 | — | — | WO | claimed |
| EP-0350287-B1 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | CHIMERIX INC (US) | 2000-09-27 | — | — | EP | claimed |
| JP-62099393-A | — | — | None | — | — | JP | disclosed |
| JP-63083094-A | — | — | None | — | — | JP | disclosed |
| WO-2010037134-A2 | MULTI-STAGE STEM CELL CARCINOGENESIS | STEMLIFELINE, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2008-03-20 | — | — | US | disclosed |
| EP-1812456-A2 | ß-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2007-08-01 | — | — | EP | disclosed |
| US-20060122144-A1 | Compounds resistant to metabolic deactivation and methods of use | KANE ROBERT R | 2006-06-08 | — | — | US | disclosed |
| WO-2006045616-A2 | β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2006-05-04 | — | — | WO | disclosed |
| EP-1581547-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004050678-A2 | COMPOUNDS RESISTANT TO METABOLIC DEACTIVATION AND METHODS OF USE | BAYLOR UNIVERSITY (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-0350287-B1 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | CHIMERIX INC (US) | 2000-09-27 | — | — | EP | disclosed |
| US-5051499-A | Phosphatides as antitumor agents | TOYO JOZO KABUSHIKI KAISHA (JP) | 1991-09-24 | — | — | US | disclosed |
| US-4921951-A | WATER SOLUBILITY, ANTITUMOR AGENTS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1990-05-01 | — | — | US | disclosed |
| US-4797479-A | ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-01-10 | — | — | US | disclosed |
| JP-S6383094-A | ETHER-TYPE NUCLEOSIDE-PHOSPHOLIPID COMPLEX | TOYO JOZO CO LTD | 1988-04-13 | — | — | JP | disclosed |
| JP-S6299393-A | NOVEL ARABINONUCLEOSIDE PHOSPHOLIPID COMPLEX | TOYO JOZO CO LTD | 1987-05-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070859-A1 | Compounds resistant to metabolic deactivation and methods of use | NAT1, NNMT, PNP | GSK3B 3508/4885ADK 189/4885TSHR 2330/4885 |
| US-20060122144-A1 | Compounds resistant to metabolic deactivation and methods of use | NAT1, NNMT, PNP | GSK3B 3508/4885ADK 189/4885TSHR 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.